AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05567952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Participants will receive 1 capsule of ritonavir every 12 hours
Study NCT05567952 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ritonavir
Description: Participants will receive 1 capsule of ritonavir every 12 hours
Study NCT05567952 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo for nirmatrelvir
Description: Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
Study NCT05994014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/CT
Description: Experimental test for detecting atherosclerosis
Study NCT06706440 — intervention group
Intervention type: OTHER
Intervention: no intervention, observational study
Description: Only data will be taken of patient's file.
Study NCT06707142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBD11
Description: TBD11 will be administered orally.
Study NCT06707142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study NCT06707142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.
Study NCT04985955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib tablet will be administered orally.
Study NCT06345963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active H-coil delivered rTMS
Description: Multiple trains of rTMS in a day, for multiple days.
Study NCT05424133 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High frequency chest wall oscillation
Description: High frequency chest wall oscillations at 13-15Hz oscillating frequency for 20 minutes twice a day for 4 weeks.
Study NCT05424133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing
Description: Active cycle of breathing technique and it will performed twice a day for 4 week intervention period for 20 minutes
Study NCT06727734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Levonorgestrel 1.5 mg
Study NCT06727734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam
Description: Piroxicam 40 mg
Study NCT06727734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal Acetate
Description: Ulipristal 30 mg
Study NCT06727734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - LNG
Description: Placebo of levonorgestrel
Study NCT06727734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Piroxicam
Description: Placebo of piroxicam
Study NCT06727734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - UPA
Description: Placebo of ulipristal acetate
Study NCT06733155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial intervention
Description: Participants completing the mammogram within the study end date will receive a $10 voucher.
Study NCT06733155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lottery intervention
Description: Participants completing the mammogram within the study end date will receive achance to win a $5000 lottery.
Study NCT06733155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Messages
Description: Participants will receive a less than 5 minute long video from an influential person. The video will be available in four languages (English, Chinese, Malay, Tamil).
Study NCT06733155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal Health Concierge
Description: Participants will be able to call a dedicated hotline for scheduling mammograms with the help of a health concierge over eight weeks of receive the the mailer.
Study NCT06733155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Only reminder mailer
Description: Receives a mail reminder with basic information about breast cancer and instructions on scheduling a mammogram.
Study NCT06739616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AUTOSIB across time
Description: Intervention will be in place across increasing time frames.
Study NCT06739616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AUTOSIB diminished reinforcement
Description: Intervention will be in place with decreasing levels of reinforcement
Study NCT06744868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THDBH120 injection (SAD)
Description: Participants received escalating single doses of THDBH120 by subcutaneous injection.
Study NCT06744868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of THDBH120 injection (SAD)
Description: Participants received single dose of placebo by subcutaneous injection.
Study NCT04885491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride (placebo)
Description: Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
Study NCT04885491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDNO
Description: PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
Study NCT05337527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beetroot juice
Description: Acute effects of beetroot juice or placebo juice ingestion
Study NCT05337527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: beetroot juice
Description: Acute effects of beetroot juice or placebo juice ingestion
Study NCT05241015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Treatment protocol; It will be applied to improve posture, strengthen muscles, eliminate shortness, increase flexibility, balance/coordination, sit up/stand up and in-bed mobilization, and improve gait. Before taking the treatment, a general evaluation will be made and as a result of this evaluation, muscle shortness, loss of strength, postural disorders and the activities and positions they have the most difficulty in daily life will be determined. Treatment programs will be shaped according to the problems determined in line with the evaluations made.
Study NCT05241015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises Group
Description: In addition to the standard physiotherapy program, sensorimotor training including the cervical region will be given to the this group. Deep cervical flexor and extensor muscles, which provide stability in the cervical region, will be trained. A Pressure Biofeedback Device will be used to train the deep cervical flexors. Both positional and kinesthetic sensory training will be provided by maintaining the stability of the cervical region by means of the laser kit that provides visual feedback.Additionally, oculomotor exercises will be given.
Study NCT05841550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG01
Description: All participants will receive the same treatment as described under arm
Study NCT05259904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: 7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
Study NCT05259904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
Study NCT05567939 — intervention group
Intervention type: OTHER
Intervention: Natural course of disease
Description: Sample and questionnaire collection
Study NCT06744868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THDBH120 injection (MAD)
Description: Participants received multiple doses of THDBH120 once weekly for four weeks by subcutaneous injection.
Study NCT06744868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of THDBH120 injection (MAD)
Description: Participants received placebo once weekly for four weeks by subcutaneous injection.
Study NCT06744153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Space Maintainer
Description: Fabrication of KOS\&MET functional space maintainer and its cementation.
Study NCT06747078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Therapy (NDT) + Core Stabilization Training
Description: In addition to the neurodevelopmental treatment of 30 minutes per day, 3 sessions per week, and a total of 24 sessions, core stabilization training was applied 3 sessions per week for 8 weeks and a total of 24 sessions. The core stabilization training session lasted 30 minutes.
Study NCT06747078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental therapy + Balance Exercises
Description: In addition to NDT, which is 30 minutes per day, 3 sessions per week and 24 sessions in total, balance training was applied 3 sessions per week for 8 weeks and 24 sessions in total. The balance exercise session lasted 30 minutes.
Study NCT06747078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental therapy
Description: NDT was applied for 60 minutes per day, 3 sessions per week, for 8 weeks and a total of 24 sessions.
Study NCT06629922 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a observational study and the participants will not receive any intervention
Study NCT06221618 — intervention group
Intervention type: OTHER
Intervention: High-frequency carotid arteries ultrasound, CCTA, Cranial MRA
Description: CCTA and carotid high-frequency ultrasound for all patients in the coronary heart disease cohort. Cranial MRA and carotid high-frequency ultrasound for all people in the stroke cohort.Carotid high-frequency ultrasound for all patients in the normal control group.All patients were treated optimally according to guidelines
Study NCT06749002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Turning based specific training along with functional Muscle training
Description: Experimental group will receive Turning based specific training protocol for 6 weeks along with functional muscle training, training will be done on alternate days.~Functional muscle training:~Details: Week 1-6: 3 days a week on alternate days.~Hip Abductors:~Side lying leg raises Single leg squatting Standing leg wall press Progressing to Adding resistance bands~Hip adductors:~Side lying adduction Standing Adduction Progress to adding resistance bands~Hip Flexors:~Standing leg lift Straight leg raises Progress to adding resistance bands~Hip Extensors:~Prone lying raises Standing single leg extension Progress to adding resistance bands~Plantarflexors/ DorsiFlexors:~Plantarflexors:~Plantarflexion against resistance Toe raises~Dorsiflexors:~Dorsiflexion against resistance Heel raises~Hip external rotators:~Sitting-externally rotate hip 0-30° Add resistance bands~Hip Internal rotators:~Sitting-internally rotate the hip 0-30° Add resistance bands.
Study NCT04886180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxiris membrane
Description: Hemofiltration treatment with Oxiris membrane connected to the ECLS circuit for 24 hours.
Study NCT04886180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prismaflex membrane
Description: Treatment by hemofiltration with PrismaFlex ST150 membrane connected to the ECLS circuit for 24 hours.
Study NCT04886180 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood tests
Description: Blood tests before and just after membrane placement and at H6, H24, H48 and H72 after membrane placement
Study NCT05674799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NDPP-NextGen
Description: NDPP-NextGen will incorporate content on preconception/prenatal health into standard NDPP. Participants will be encouraged to make sustainable improvements in diet and activity, but without pre-set goals to better accommodate diverse, low-income populations. Upon pregnancy, recommendations will adjust to support appropriate GWG, breastfeeding, and postpartum weight loss. We will provide education on diet and activity during pregnancy/postpartum, including sufficient energy intake and exercise safety to support the growing fetus. NDPP-NextGen will include 3 strategies to better engage young women. (1) Pre-sessions to increase knowledge of diabetes risks, self-efficacy, and readiness to change using motivational interviewing techniques. (2) Delivering classes remotely (via phone- and video-conference) to facilitate participation regardless of inclement weather, dependent care, illness, transportation, etc. (3) Offering classes specially for young women to increase personal relevance.
Study NCT04944472 — intervention group
Intervention type: BEHAVIORAL
Intervention: HDKQ questionnaire
Description: Studying the possibilities of perceiving information on the primary prevention of cardiovascular diseases in persons suffering from hypertension through the social network Instagram
Study NCT04886180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood tests
Description: Blood tests before and just after membrane placement and at H6, H24, H48 and H72 after membrane placement
Study NCT05602857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: The BT program has multiple difficulty levels, and each child will progress at an individual pace tailored to their balance skills. Training sessions will emphasize top-down control of balance and contain a combination of dynamic and static balance exercises. Children and their parents will receive written step-by-step instructions, with photos, verbal and/or video instructions on their private OneDrive folder.~To monitor compliance, whether the exercises were done properly, and evaluate a child's progress, the parent/guardian will film the sessions, and upload the video to OneDrive, so we can score the child's performance and provide them with a progress tracking chart.~Every child will be given the equipment needed to do the balance exercises: two wooden beams that will make a 12-foot balance beam, four small wooden cubes that will raise the balance beam 5 inches off the ground, a wobble board, a hopscotch mat, one roll of painter's tape, one measuring tape, a bell, a small book.
Study NCT06749002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: turning based specific training.
Description: Week 1:~90 Degrees turns on the spot~Visual cues to follow~Week 2-3:~90 degrees turns on the spot~Figure of 8 walking~Visual cues to follow~Week 4-5:~90 Degrees turns on the spot~Figure of 8 walking~Step across body~Braiding~Week 6:~90 degree turns on the spot~Figure of 8 walking~Step across body~Braiding~Visual cues to follow~Obstacle avoidance
Study NCT06748534 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plus Lens Addition (+0.75 D)
Description: Participants in this group were provided with +0.75 D lenses, designed to assist in alleviating strain caused by accommodative infacility by reducing the demand on the eye's focusing mechanism.
Study NCT05602857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Training
Description: Children assigned to MT will be asked what kind of music and what performers they like best, and what songs they like most. After those open-ended questions, they will be asked about specific songs, guided somewhat by the child's previous answers, and will watch short excerpts from music videos to see which the child would like to listen to and watch during Week 1 of the MT program. This is all to guide the selection of music videos the child will enjoy and might give some thought to.~They will receive 10 music videos per week, through the child's private OneDrive folder, from which they can choose 4 to watch every session. Children will be instructed to not do anything else, but simply watch the videos or listen with their eyes closed.~To monitor compliance, and to check if the child was paying attention to the music videos or just having them play in the background while doing something else, the parent/guardian will film the MT sessions, and upload the video to OneDrive.
Study NCT06375824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufei Recipe
Description: Bufei Recipe: Roasted Astragalus, Codonopsis pilosula, Walnut kernels, Sichuan Fritillaria, Angelica sinensis, Stir fried Purple Su Zi, Honey Baibu, Roasted Purple Aster, etc. Take 1 dose daily, 5 days a week.
Study NCT06375824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bufei Recipe placebo
Description: The placebo was prepared using 5% of the drug, with color, odor, taste, appearance, and weight similar to the experimental group drug, and packaging consistent with the experimental group drug.
Study NCT05817331 — intervention group
Intervention type: OTHER
Intervention: Carer Treatment Preference Myelodysplasia Questionnaire
Description: Caregiver-reported outcome measure in MDS
Study NCT05817331 — intervention group
Intervention type: OTHER
Intervention: Clinician Treatment Preference Myelodysplasia Questionnaire
Description: Clinician-reported outcome measure in MDS
Study NCT06495580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optic Nerve Stimulation
Description: Anterograde Stimulation of the Optic Neve.
Study NCT01004315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC-7483
Study NCT06748534 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Vision Therapy Using HART Chart
Description: Intervention Details: Participants in this group underwent vision therapy sessions utilizing the HART chart, aimed at enhancing their accommodative flexibility through repetitive focusing exercises.
Study NCT06749704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: High protein diet
Study NCT06749704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal Protein diet
Description: Normal protein diet
Study NCT06748872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepletion
Description: Cylcophosamide and Fludarabine
Study NCT06748872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-T cells (MDG1015)
Description: TCR-T cells (MDG1015)
Study NCT06750081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Exercises to improve locomotor abilities of children with CP
Study NCT06750081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Designed rehabilitation program
Description: Program of exercises to enhance abilities
Study NCT05275738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide
Description: Study tablets for nicotinamide are produced by Blackmores Ltd.
Study NCT05275738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study tablets for placebo are produced by Blackmores Ltd.
Study NCT06749860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin + tislelizumab + bevacizumab
Description: Disitamab Vedotin, dosing regimen: 2.0 mg/kg, intravenous infusion, infusion should be about 30-90 minutes (usually about 60 minutes), every 21 days a cycle, the first day of administration, continuous use.~Tislelizumab, dosing regimen: 200 mg administered by intravenous infusion every 21 days in a cycle on the first day, continuous.~Bevacizumab, dosing regimen; 7.5 mg/kg administered by intravenous infusion every 21 days in a cycle on the first day of continuous use.
Study NCT04661930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TriCor® 145mg tablets
Description: Fenofibrate; 145 mg daily (1/day); oral administration; 10 days
Study NCT04661930 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
Study NCT04661930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: All participants will otherwise receive usual medical care
Study NCT04661930 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: All participants will otherwise receive usual medical care
Study NCT05817331 — intervention group
Intervention type: OTHER
Intervention: Patient Treatment Preference Myelodysplasia Questionnaire
Description: Patient-reported outcome measure (PROM) in MDS
Study NCT04288492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory biofeedback
Description: Repeat the inspiration and exhalation breaths for a fixed period of time using a biofeedback device (ResCalm)
Study NCT05580796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSH01 injection
Description: TCR-T cell injection
Study NCT04993391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS111(AP-L1898 Capsules)
Description: 40 mg, QD
Study NCT04993391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS111(AP-L1898 Capsules)
Description: 80 mg, QD
Study NCT04993391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS111(AP-L1898 Capsules)
Description: 160 mg, QD
Study NCT04993391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS111(AP-L1898 Capsules)
Description: 240 mg, QD
Study NCT04993391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS111(AP-L1898 Capsules)
Description: 320 mg, QD
Study NCT06750991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDR-CHOP
Description: Rituximab 375 mg/m2 D1 Cyclophosphamide 750 mg/m2 D2 Doxorubicin 50 mg/m2 D2 Vincristine 1.4 mg/m2 D2 Prednisone 69 mg.m2 D2-6 Chidamide 20 mg/d D1,4,8,11 Decitabine 10 mg/m2 D-5 - -1
Study NCT06751316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Pulpectomy
Description: Removal of radicular pulp tissue, placing Zinc Oxide/Eugenol and covered by stainless steel crown